Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WVE-N531 in Duchenne Muscular Dystrophy
NCT04906460Phase 2Active, not recruiting
- Sponsor
- Wave Life Sciences
- Start
- Sep 2021
- Primary completion
- Oct 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
A Phase 2 trial of WVE-N531 in Duchenne muscular dystrophy (DMD), sponsored by Wave Life Sciences. Started Sep 2021; status: active, not recruiting.
02
Drugs
WVE-N531
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04906460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906460.